6 October 2014 in Mass Spectrometry Reviews
1 March 2014 in Developmental & Comparative Immunology
1 June 2021 in Carbohydrate Research
Tandem mass spectrometry has found widespread application as a powerful tool for the characterization of linear and branched oligosaccharides. Though the technique has been applied to the analysis of cyclic oligosaccharides as well, the underlying fragmentation mechanisms have hardly been investigated. This study focuses on the mechanistic aspects of the gas-phase dissociation of protonated β-cyclodextrins. Elucidation of the dissociation mechanisms is supported by tandem mass spectrometric experiments and by experiments on di- and trimethylated cyclodextrin derivatives. The fragmentation pathway comprises the linearization of the macrocyclic structure as the initial step of the decomposition, followed by the elimination of glucose subunits and the subsequent release of water and formaldehyde moieties from the glucose monomer and dimer fragment ions. Linearization of the macrocycle occurs due to proton-driven scission of the glycosidic bond adjacent to carbon atom C1 in conjunction with the formation of a new hydroxy group. The resulting ring-opened structure further decomposes in charge-independent processes forming either zwitterionic fragments, a 1,4-anhydroglucose moiety, or a new macrocyclic structure, that is lost as a neutral, and an oxonium ion. Since the hydroxy group formed at the ring-opening site can be regarded as the non-reducing end of the linearized structure, the fragment ion nomenclature commonly used for linear and branched oligosaccharides, which relies on the designation of a reducing and a non-reducing end, can also be applied to the description of fragment ions derived from cyclic structures.
14 February 2013 in Clinical Chemistry and Laboratory Medicine (CCLM)
Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. Conclusions: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.
7 May 2014 in Journal of the American Society for Mass Spectrometry